Next 10 |
home / stock / ablyf / ablyf news
Karyopharm (KPTI) slumped 17% in the pre-market yesterday, ahead of data from a mid stage study of selinexor in treatment-resistant multiple myeloma. A couple of years ago, this same drug was pitted against Darzalex in the same indication and showed similar efficacy. An FDA filing was planned ...
Ablynx ( OTCPK:ABLYF ) completes enrollment of 180 infants in a Phase 2b clinical trial, RESPIRE , assessing inhaled drug candidate ALX-0171 for the treatment of respiratory syncytial virus (RSV) infection. More news on: Ablynx NV, Sanofi, Healthcare stocks news, Read more ...
Ablynx's ( OTCPK:ABLYF ) vobarilizumab failed to demonstrate a dose response after 24 weeks of treatment in a Phase 2 dose-ranging study in patients with moderate-to-severe active seropositive systemic lupus erythematosus (SLE). More news on: Ablynx NV, Healthcare stocks news, Read m...
Dosing is underway in a Japan-based Phase 2 clinical trial evaluating Ablynx's ( OTCPK:ABLYF ) ALX-0171 inhaled Nanobody for the treatment of respiratory syncytial virus (RSV) infections. More news on: Ablynx NV, Healthcare stocks news, Read more ...
Ablynx NV ( OTCPK:ABLYF ): FY Net loss of €108.5M Revenue of €55.5M (-34.9% Y/Y) Press Release More news on: Ablynx NV, Ablynx NV, Earnings news and commentary, Healthcare stocks news,
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss Sanofi’s ( SNY ) takeover offer for Belgian biotech Ablynx ( ABLYF ). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk ( NVO ), noting that euro 30.50 per share offer undervalued ...
We first covered Ablynx ( OTCPK:ABLYF ) in September 2017, ahead of an important catalyst for the company. The note was published ahead of the data readout from the phase 3 HERCULES study. We had noted that ABLYF was a buy ahead of the event. The event played out as expected and ABLYF shares...
Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions...
Novo Nordisk's bid on Ablynx On January 8, 2017, Novo Nordisk ( NVO ), the Danish multinational pharmaceutical giant, made a public announcement that it wanted to acquire the Belgian biotech company Ablynx ( ABLX ) ( ABLYF ). Novo Nordisk offered $33 per share, which means a total amount ...
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered ...